Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Personalized medicine

Benjamin A Raby, MD, MPH
Section Editor
Anne Slavotinek, MBBS, PhD
Deputy Editor
Jennifer S Tirnauer, MD


With the rapid pace of progress in the fields of biotechnology, genetics, and genomics, molecular genetic profiling may soon become an integral tool for clinicians to guide individualized management of many medical conditions. Personalized medicine (also termed personalized genomics, genomic medicine, or precision medicine) refers to the application of patient-specific profiles, incorporating genetic and genomic data as well as clinical and environmental factors, to assess individual risks and tailor prevention and disease-management strategies.

This topic will review the current state of personalized medicine and the challenges and obstacles confronted in the broad implementation of genomics in the clinic.

The principles and techniques that underlie these tests, and counseling for genetic testing, are discussed separately.

(See "Tools for genetics and genomics: Gene expression profiling".)

(See "Principles and clinical applications of next-generation DNA sequencing".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Genetics Home Reference http://ghr.nlm.nih.gov/glossary=personalizedmedicine (Accessed on February 17, 2015).
  2. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006; 6:223.
  3. Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346:1480.
  4. Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007; 33:22.
  5. Collins RE, Wright AJ, Marteau TM. Impact of communicating personalized genetic risk information on perceived control over the risk: a systematic review. Genet Med 2011; 13:273.
  6. Wright AJ, French DP, Weinman J, Marteau TM. Can genetic risk information enhance motivation for smoking cessation? An analogue study. Health Psychol 2006; 25:740.
  7. Sanderson SC, Michie S. Genetic testing for heart disease susceptibility: potential impact on motivation to quit smoking. Clin Genet 2007; 71:501.
  8. Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5:e9220.
  9. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011; 364:524.
  10. Li C. Personalized medicine - the promised land: are we there yet? Clin Genet 2011; 79:403.
  11. Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 3: challenges facing health care plans in implementing coverage policies for pharmacogenomic and genetic testing. P T 2010; 35:670.
  12. Coote JH, Joyner MJ. Is precision medicine the route to a healthy world? Lancet 2015; 385:1617.
  13. Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16:1324.
  14. https://am.asco.org/ascos-targeted-agent-and-profiling-utilization-registry-tapur-study.
  15. http://www.mdanderson.org/publications/oncolog/previous-issues/2015-january/impact2-study-tests-benefits-of-personalized-cancer-treatment-based-on-molecular-profiling.html.
  16. https://www.clinicaltrials.gov/ct2/show/NCT02029001.
  17. https://www.clinicaltrials.gov/ct2/show/NCT02534675.
  18. https://www.clinicaltrials.gov/ct2/show/NCT02508662.
  19. US Department of Health and Human Services. www.hhs.gov. (Accessed on May 03, 2011).
  20. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372:793.
  21. US Food and Drug Administration. http://www.fda.gov (Accessed on May 03, 2011).
  22. Jain KK. Applications of AmpliChip CYP450. Mol Diagn 2005; 9:119.
  23. Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012; 18:1041.
  24. Minon JM, Gerard C, Senterre JM, et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008; 48:373.
  25. Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118:1340.
  26. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011; 11:5.
  27. Wise J. Personal genome service launches in UK. BMJ 2014; 349:g7435.
  28. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm (Accessed on December 02, 2013).
  29. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435003.htm (Accessed on April 04, 2016).
  30. 23andMe press release http://mediacenter.23andme.com/blog/new-23andme/ (Accessed on April 04, 2016).
  31. Hayden EC. "Out of regulatory limbo, 23andMe resumes some health tests and hopes to offer more." Nature News. http://www.nature.com/news/out-of-regulatory-limbo-23andme-resumes-some-health-tests-and-hopes-to-offer-more-1.18641 (Accessed on April 04, 2016).
  32. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435003.htm (Accessed on August 24, 2017).
  33. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551185.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery (Accessed on April 07, 2017).
  34. Wright CF, Hall A, Zimmern RL. Regulating direct-to-consumer genetic tests: what is all the fuss about? Genet Med 2011; 13:295.
  35. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009; 461:724.
  36. Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem 2011; 57:518.
  37. Zehnbauer B. Direct-to-consumer genetics testing--fair comparisons? Clin Chem 2011; 57:369.
  38. Zettler PJ, Sherkow JS, Greely HT. 23andMe, the Food and Drug Administration, and the future of genetic testing. JAMA Intern Med 2014; 174:493.
  39. Coughlin SS. Toward a road map for global -omics: a primer on -omic technologies. Am J Epidemiol 2014; 180:1188.
  40. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134:714.
  41. Gross RW, Han X. Lipidomics at the interface of structure and function in systems biology. Chem Biol 2011; 18:284.
  42. Puri R, Duong M, Uno K, et al. The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opin Drug Discov 2012; 7:63.
  43. Quinn PJ, Rainteau D, Wolf C. Lipidomics of the red cell in diagnosis of human disorders. Methods Mol Biol 2009; 579:127.
  44. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726.
  45. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.
  46. Friedman DR, Weinberg JB, Barry WT, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:6947.
  47. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008; 299:1320.
  48. Walt DR, Kuhlik A, Epstein SK, et al. Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genet Med 2011; 13:63.
  49. http://deansnewsletter.stanford.edu/archive/09_28_09.html (Accessed on September 28, 2009).
  50. Hauskeller C. Direct to consumer genetic testing. BMJ 2011; 342:d2317.
  51. Ormond KE, Wheeler MT, Hudgins L, et al. Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375:1749.
  52. Samani NJ, Tomaszewski M, Schunkert H. The personal genome--the future of personalised medicine? Lancet 2010; 375:1497.
  53. Creighton S, Almqvist EW, MacGregor D, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet 2003; 63:462.